PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort
PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort
DESIGN Longitudinal prospective observational multicentre study.

 Primary objective:

 Understand the immune mechanisms driving COVID-19 disease in patients with a history of lung
 disease
INTRODUCTION

 1.1 BACKGROUND

 Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is a new rapidly spreading
 infectious disease with no proven treatment options. The virus causes a spectrum of disease
 ranging from mild coryzal symptoms to severe respiratory compromise requiring ventilatory
 support. Guidance from Public Health England identifies several groups that are at risk of
 severe disease including the elderly and individuals with chronic lung disease. Additionally,
 there is also debate over the role of corticosteroids with some hospital guidelines
 recommending their use despite WHO guidance contradicting this due to concerns that they may
 impair antiviral immunity and worsen disease. The mechanisms driving severity of disease in
 certain individuals infected with COVID-19 are poorly understood. We urgently need to
 understand these mechanisms to facilitate rapid development of novel effective therapies and
 vaccines

 1. Immunosusceptibility to severe COVID-19 disease

 There are several putative mechanisms through which SARS-CoV-2 could drive greater disease
 severity in pre-disposed individuals. These include:

 1. Impaired innate anti-viral immune responses

 Following viral entry, the innate immune response to respiratory viruses involves
 induction of the type I and III interferons (IFN). This initiates a cascade that
 triggers expression of a range of interferon-stimulated genes expressing proteins that
 act in concert to limit viral replication. Chronic lung diseases, particularly asthma,
 cystic Fibrosis (CF) and COPD are associated with impaired or dysregulated induction of
 interferon to commonly encountered viruses such as rhinovirus and influenza and similar
 dysregulation may occur with SARS-CoV-2. Inhaled interferon-β is currently in trials as
 an anti-viral therapy for asthma and COPD.

 2. Exaggerated inflammatory responses to viral infection

 Common respiratory viral infections such as influenza and respiratory syncyitial virus
 (RSV) can promote viral pathology mediated by antibodies and T cell responses. Early
 evidence suggests that severe COVID-19 disease is associated with hyperinflammation, a
 feature that could be directly driven by virus burden or occur due to independent
 hyperactivation of the immune system. Human coronavirus infections including SARS-CoV
 can induce immunopathology in the lungs through a number of different mechanisms
 including antibody enhancement of SARS-CoV infection by human macrophages. Significant
 increases in CD4 and CD8 expressing pro-inflammatory cytokines have been shown in severe
 SARS-CoV disease compared to mild/moderate disease.

 Accordingly, there has been considerable interest in a potential role of repurposing
 existing immunosuppressive therapies for treatment of severe COVID-19. The key mediators
 and pathways that drive hyperinflammation in COVID-19 are unclear and greater
 elucidation of these processes will inform repurposing of existing therapies or
 development of novel approaches to effective treatment. The implication of baseline
 dysregulated T cell responses such as those seen in chronic lung disease (e.g. asthma,
 COPD, Cystic Fibrosis) is again unclear and requires further mechanistic understanding.
 As such it is, as yet, unclear whether immunosuppressive therapies currently in clinical
 trials will be beneficial or harmful in these large cohorts of susceptible patients.

 3. Dysregulated interferon-dependent endothelial function to COVID-19

 Acute respiratory distress syndrome (ARDS) is characterised by hydrostatic pulmonary
 oedema, elevated pulmonary vascular resistance and coagulopathy, there is disruption of
 endothelial function with dysregulated release of the endothelially derived vasoactive
 hormones. Circulating levels of endothelin-1 are raised in patients with ARDS[16],
 likely due to increased production and decreased clearance in the lungs potentially
 regulated by Angiopoietin-1.

 Severe SARS-CoV-2 infection is associated with cytokine storm. Raised serum levels of a
 number of key inflammatory cytokines including IFN-gamma, TNF-alpha, IP10, IL-8 and
 IL-10 and elevated levels of IL-6 are strongly associated with mortality. IL-6 release
 is synergistically induced by IFN-gamma and TNF-alpha and in a positive feedback
 mechanism, a low dose of IL-6 strongly enhances the cellular responses to IFN-alpha and
 modulates interferon-stimulated gene expression. In an experimental murine model, we
 found that infection with rhinovirus with IFN co-stimulation leads to elevated
 bronchoalveolar lavage levels of IL-6 (Singanayagam et al, unpublished observations).
 These data suggest that in patients with severe COVID-19, a hyperinflammatory process
 ensues and we hypothesise that through dysregulated and unchecked IFN production, key
 vasculo-inflammatory interferon-stimulated genes including IP10 and ET-1 drive worse
 outcomes with increased parenchymal and pulmonary vascular inflammation. This results in
 a dichotomy whereby initial IFN induction is required to limit viral replication, but
 late unchecked production can worsen pathophysiology. This is supported by emerging
 clinical data suggesting a unique phenotype to SARS-CoV-2 critical care patients
 characterised by severe hypoxia with near normal lung compliance.

 4. Altered viral entry receptor expression: Recent data indicates SARS-CoV-2 utilises
 angiotensin-converting enzyme (ACE)2 as a receptor for viral attachment and also the
 protease TMPRSS2 which cleaves the spike(S) protein to allow fusion of the virus with
 cellular membranes. ACE2 and TMPRSS2 are frequently co-expressed in the pulmonary
 epithelium. A recent study also showed that ACE2 is an interferon stimulated gene
 (ISG)(i.e. directly induced by the anti-viral response) and therefore, SARS-CoV-2 might
 upregulate its own receptor to propagate infection. Recent data indicates that smokers
 and subjects with chronic obstructive pulmonary disease (COPD) have increased pulmonary
 ACE2 expression suggesting that chronic lung disease might facilitate greater infection
 with SARS-CoV-2. Conversely, ACE2 expression protects against acute lung injury in the
 context of acid aspiration or sepsis and therefore, if ACE2 induction by SARS-CoVs is
 impaired in chronic lung disease, this could predispose to adverse outcome.

 5. Increased secondary bacterial and/or fungal infections

 In early case series, secondary infections have been observed more frequently in subjects
 with severe COVID-19 disease. Secondary bacterial infection is a well-recognised phenomenon
 following rhinovirus, influenza or respiratory syncytial virus and may be mechanistically
 driven by a range of possible mechanisms including macrophage phagocytosis or neutrophil
 elastase-mediated cleavage of anti-microbial peptides. These processes may be worsened by use
 of corticosteroids28 and, notably, a greater proportion of patients with secondary infections
 following COVID-19 had been prescribed steroids.

 Invasive fungal disease consistent with aspergillosis has also been observed for both severe
 acute respiratory syndrome coronavirus (SARS-CoV-2003) and Middle East Respiratory Syndrome
 coronavirus (MERS-CoV), and anecdotal reports of post-mortems in patients with COVID-19 from
 China suggest that Aspergillus pulmonary infections occur. These data are early warning signs
 that secondary invasive fungal infections may present an increasingly serious complication in
 patients affected with COVID-19 as the pandemic progresses. Understanding the mechanistic
 basis for immune susceptibility to secondary bacterial/fungal infection and an ability to
 prevent these secondary infections could be a key step towards improving outcomes from the
 disease.

 1.2 RATIONALE FOR CURRENT STUDY

 In this study, the investigators will analyse blood and airway samples from individuals with
 confirmed COVID-19 to understand the immune mechanisms that lead to severe disease. We will
 elucidate specific mechanisms that drive more severe pathology in higher risk individuals
 such as those with chronic lung disease. Through detailed immunoprofiling, we will identify
 key pathways and druggable targets to exploit in future clinical intervention studies.

 Hypotheses:

 1. High risk individuals including individuals with chronic lung disease have impaired
 anti-viral immune responses to SARS-CoV-2, increasing virus-induced inflammation.

 2. Interferon-dependent endothelial dysfunction drives pathogenicity in SARS-CoV-2
 infection.

 3. Susceptibility to secondary bacterial and fungal infection in chronic lung disease is
 related to selective pathway defects in innate immune function.

 2. STUDY OBJECTIVES

 Primary objective:

 1. Understand the immune mechanisms driving COVID-19 disease in patients with a history of
 lung disease

 Secondary objectives

 1. Identify immune correlates of protection and lung pathology in SARS-CoV-2 infection.

 2. Analysis of endothelial function in mild and severe COVID-19 patients and ex vivo using
 virus stimulated blood-derived endothelial cells from patients with COVID-19.

 3. Evaluation of changes in upper/lower airway microbiota and mycobiota occurring during
 COVID-19.

 4. Evaluation of ex vivo peripheral blood immune responses to viral, bacterial and fungal
 stimuli in patients with COVID-19 and chronic lung disease in comparison to patients
 with COVID-19 and no chronic lung disease.

 5. Analysis of quality of life impact of COVID-19 infection in chronic lung disease.

 3. STUDY DESIGN

 Through a 24 month prospective longitudinal multicentre (Royal Brompton & Harefield NHS Trust
 Chelsea and Westminster NHS Foundation Trust, and Imperial College Healthcare NHS Trusts)
 observational study, the study team will analyse blood, sputum and nasal sampling alongside
 non-invasive EndoPAT device testing in a total pf 230 subjects. The study team will obtain
 peripheral blood, sputum, nasal lavage, brushings and nasal synthetic absorptive matrix (SAM)
 samples and perform non-invasive EndoPAT testing on the day of hospital presentation and at
 weekly intervals during inpatient setting and then during outpatient visits post-discharge
 over a 12 month follow-up period. The study team will collect clinical information including
 demographics, routine laboratory investigations, clinical symptom scores and outcomes. Linked
 pseudoanonymised radiology imaging will also be transferred for analysis.

 Spontaneously expectorated sputum, nasal lavage, brushings and nasal synthetic absorptive
 matrix (SAM) samples will be taken and processed as previously described and stored at -800C
 for downstream analyses including ELISA/MSD, viral load measurement and microbiome analysis.
 Venous blood (60mls) will be taken into Lithium Heparin tubes and PAXgene RNA tubes and
 transferred to Imperial College (RBH) for processing and storage. PBMCs will be extracted for
 in vitro stimulation assays and whole blood (1ml) and serum (2mls) isolated and stored at
 -80oC for further analysis. PAXgene tubes will be stored at -80C for further host genetic
 sequencing analysis. Further immunological analysis using yeast surface display for serum
 antibody profiling, single B cell sorting to generate monoclonal antibodies and ELISPOT to
 analyse CD4 and CD8 T cell ELISPOT to SARS CoV-2 peptide pools. Further deep immunological
 profiling using cytokine analysis, PBMC cytokine response to viral (or viral PRR agonist),
 fungal stimuli, yeast surface display for serum antibody profiling, single memory B cell
 expression cloning will be carried. CD4 and CD8 T cell ELISPOT will be performed as
 previously described. Non-invasive EndoPAT testing will also be performed as previously
 described.
Inclusion Criteria:

 1. All patients ≥16 years old with confirmation of COVID-19

 2. All patients ≥ 16 years old with chronic lung disease (CF, non-CF bronchiectasis,
 asthma, COPD or Idiopathic Pulmonary Fibrosis) or with no evidence of prior chronic
 lung disease

 3. Healthy volunteers

 Exclusion Criteria:

 None